Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas–kidney transplantation under antibody preconditioning
- 1 December 2004
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (10) , 3107-3112
- https://doi.org/10.1016/j.transproceed.2004.11.092
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prevention and treatment of cytomegalovirus infection in solid organ transplant recipientsCurrent Opinion in Infectious Diseases, 2004
- CYTOMEGALOVIRUS INFECTION IN ORGAN-TRANSPLANT RECIPIENTS: DIAGNOSTIC VALUE OF PP65 ANTIGEN TEST, QUALITATIVE POLYMERASE CHAIN REACTION (PCR) AND QUANTITATIVE TAQMAN PCRTransplantation, 2004
- Tolerogenic immunosuppression for organ transplantationThe Lancet, 2003
- Cytomegalovirus in Renal TransplantationJournal of the American Society of Nephrology, 2001
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999
- A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF ORAL ACYCLOVIR VERSUS ORAL GANCICLOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS1Transplantation, 1998
- Infectious disease complications of renal transplantationKidney International, 1993
- THE LONG PERSISTENCE OF CMV DNA IN THE BLOOD OF RENAL TRANSPLANT PATIENTS AFTER RECOVERY FROM CMV INFECTIONTransplantation, 1993
- Management and Prevention of Cytomegalovirus Infection After Renal TransplantationMayo Clinic Proceedings, 1992